Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM-1 in Transient Insomnia
NCT03331042Phase 3Completed
- Sponsor
- Sequential Medicine Ltd.
- Start
- Oct 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of diphenhydramine, zolpidem and lorazepam in Insomnia (4 arms), sponsored by Sequential Medicine Ltd. Primary endpoint: Total Sleep Time at 8 hours. Started Oct 2017; status: completed.
02
Drugs
diphenhydraminezolpidemlorazepam
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03331042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03331042.